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THE initiating phase of skin carcinogenesis in the mouse can be induced not
only when the agent is applied locally but also when administered systemically,
as has been demonstrated with 9: 10-dimethyl-1: 2-benzanthracene (Graffi,
Scharsach, and Heyer., 1955; Haran and Berenblum, 1956) and with urethane
(Haran and Berenblum, 1956; Berenblum and Haran-Ghera, 1957). [2-Acetyl-
aminofluorene, which is not an initiator for skin carcinogenesis when applied
locally (Price, 1947; Salaman and Roe, 1953), does have that action when given
by mouth (Ritchie and Saffiotti, 1955).]
Since initiating action by local application can also be induced with other
carcinogenic compounds, such as 3: 4-benzpyrene (Berenblum, 1941; Mottram,
1944; Friedewald and Rous, 1944a), 20-methylcholanthrene (Kline and Rusch,
1944; Friedewald and Rous, 1944b; Berenblum and Shubik, 1947), and
1: 2: 5: 6-dibenzanthracene (Berenblum and Shubik, 1947), it was thought
desirable to test also these systemically (by mouth), and to compare theirpotencies,
under these conditions, with that of 9: 10-dimethyl-1: 2-benzanthracene.
METHOD
The animals used in these experiments were female Swiss mice, bred in these
laboratories by brother-sister mating for 16-18 generations. They were 2-3
months old at the start of the experiment, kept in plastic cages, 8-10 mice per
cage, and housed in an air-conditioned room at 21-23' C. They were fed on
Purina Laboratory Chow, and water ad libitum.
For initiating action, the mice were given a single feeding, by stomach tube,
of0.3 mnil. ofa 1.0 per cent solution, inpolyethylene glycol-400, ofthe 4 compounds,
9: 10-dimethyl-1 :2-benzanthracene (DMBA), 20-methylcholanthrene (MCA),
3: 4-benzpyrene (BP), and 1: 2: 5: 6-dibenzanthracene (DBA), respectively.
For promoting action, a 5 per cent solution of croton oil in medicinal liquid
paraffin was applied, with a glass rod, to an area of skin about 2 x 2 cm. in the
dorsal region, the hair of the parts being previously clipped with fine scissors.
This treatment was repeated twice-weekly for 32 weeks.
The resulting skin tumours (papillomas) were charted at their first appearance,
and fortnightly thereafter. Papillomas that regressed within 2 weeks of their
first appearance were not listed in the final records. The average latent periods
were based on the times of appearance of the first tumours per animal, as onI. BERENBLUM AND NECHAMA HARAN-GHERA
previous occasions. They represent, therefore, average latent period with respect
to animal response, rather than to the cell population under treatment.
RESULTS
The tumour yields, the average numbers of tumours per animal, and the
average latent periods, are summarized in Table I. The corresponding values
at the end of the 20th week of croton oil treatment are summarized in Table HI (for
reasons to be discussed below).
TABLE I.-Development of Tumours of the Skin in Mice Receiving Various
Hydrocarbons by Mouth, followed by Repeated Skin Applications of Croton Oil
Average
Average number latent
Mice bearing papillomas period
Initiation* Promotion papillomas/survivors per animal (weeks)
DMBA . Croton oil x 64 . 24/26 92% . 8±1-5 . 9
MCA . ,, ,, ,, ,, .. 20/25 80% . 3±0-4 16
BP . ,, ,, ,, ,, . 14/18 78% . 08±0-2 . 23
DBA . ,,,,,,,, . 12/23 52% . 0-8±0.2 . 20
(control) . ,, ,,,,,, . 2/21 10% 0-09±0-06 . 29
*3 mg. in polyethylene glycol-400-single dose by mouth.
TABLE II.-As in Table I: Results after only 20 Weeks ofCroton Oil Treatment
Average
Average number latent
Mice bearing papillomas period
Initiation* Promotion papillomas/survivors per animal (weeks)
DMBA . Croton oil X 40 . 24/26 92% . 8-2±15 . 9
MCA . ,,,,,, , . 14/25 56% . 1.1±0*3 . 12
BP . ,, ,, ,, ,, . 4/19 21% . 0 2±0 09 . 141
DBA .. 7/24 29% . 0'3i01 . 14
- (control) . ,,,,,,,, . 0/21 0% -
*As in Table I.
The results show that while all four compounds, administered by mouth,
induce the initiating phase of skin carcinogenesis in the mouse, DMBA is by far
the most potent for this action.
DISCUSSION
The fact that all the four compounds tested (DMBA, MCA, BP, and DBA)
can induce the initiating phase of skin carcinogenesis in the mouse when
administered orally, suggests that systemic initiating action is not a freak
phenomenon on the part ofsome unusual compound, but represents a fundamental
aspect of skin carcinogenesis. If, as seems likely from tangential evidence
(Berenblum, 1956), initiating action involves a prior metabolic conversion of the
compound to some metabolite, attractive possibilities are opened up for the
future study of the mechanism of carcinogenesis in biochemical terms.
With regard to the actual values obtained in these experiments, DMBA was
found to be by far the most potent of the four compounds for initiating action by
mouth, while BP and DBA were found to be relatively weak.
The variations in average latent periods (Table I) call for some comment,
since no such variations were observed when these compounds were tested by
local application (Berenblum and Shubik, 1947). In the latter experiments, the
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croton oil treatment was only continued for 20 weeks. The corresponding data,
at the 20th week, in the present experiment, also indicate a diminution in the
differences in latent periods (Table II). As already suggested by us in another
connection (Berenblum and Haran-Ghera, 1957), the differences in latent periods
inprolonged experiments may be partly explained by" background " carcinogenesis
by the croton oil itself. A further factor, to account for this, is connected with
the fact that the values for latent periods refer to the times of appearance of the
first tumours only per mouse, which, in the case of a potent initiator, would be
likely to show less spread in the incidence curve than with a weak initiator, and
this would be accentuated in long-term experiments. A single tumour appearing
at the 32nd week, in a group in which the other tumours are few and appear
early, would cause the average latent period for the whole group to be exaggeratedly
delayed.
Thus, the conflict between the original thesis of Berenblum and Shubik (1947)
that on the basis of the two-stage hypothesis of skin carcinogenesis, the tumour
incidence is dependent on initiating action and the latent period only on promot-
ing action, and the recent results of Roe (1956a, 1956b), Salaman and Roe (1956a
1956b), and Klein (1956) that in prolonged experiments, the initiator does appear
to affect the latent period, could only be resolved (a) by finding a promoting
agent without "background" carcinogenic action, and (b) by more accurate
mathematical analysis of data from large-scale experiments, preferably based on
latent periods that are derived from all the induced tumours of the skin, and not
merely from the first tumour per animal.
SUMMARY
9: 10-dimethyl-1: 2-benzanthracene, 20-methylcholanthrene, 3: 4-benzpyrene
and 1: 2: 5: 6-dibenzanthracene, were found to act as initiators for skin carcino-
genesis in the mouse when administered by mouth.
Of these four compounds, 9: 10-dimethyl-1: 2-benzanthracene was the most
potent for this action.
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